Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Csoszi, T; Anton, A; Turner, N; Casas, MI; Morales, S; Alba, E; Calvo, L; De La Haba-Rodriguez, J; Ramos, M; Murillo, L; Santaballa, A; Alonso-Romero, JL; Sanchez-Rovira, P; Corsaro, M; Huang, X; Thallinger, C; Kahan, Z; Gil-Gil, M – 2022